THE DIAGNOSTIC AND PROGNOSTIC VALUE OF THE DETERMINATION OF MATRIX-METALLOPROTEAS IN THE URINE OF PATIENTS WITH URINARY BLADDER CANCER
https://doi.org/10.24884/1561-6274-2009-13-1-87-89
Abstract
THE AIM. To study the influence of the depth of the invasion and degree of the differentiation of the tumor processes on the level of matrix-metalloproteas 2 and 9 in the urine of the patients with urinary bladder cancer. PATIENTS AND METHODS. 71 patients with urinary bladder cancer were evaluated. The comparison group consisted of 14 patients with chronic cystitis, and the control group consisted of 45 patients, without any urinary bladder problems, obstruction and infection of urinary tract. The level of metaloproteas was determined with the cymography method. RESULTS. Was proven that the proteolisis ferments of urine MMP-2 and MMP-9 are high sensitive characteristics of the presence of urinary bladder cancer, and their concentration depends on the depth of the invasion and differentiation stage of the tumor and shows it’s prognosis on the diseases flow. CONCLUSION. For the diagnostics and noninvasive determination of the depth of the invasion and the stage of the differentiation of the urinary bladder cancer it is reasonable to determine the levels of MMP-2 and MMP-9 in the urine by cymography method.
About the Authors
A. S. Al-Shukri
Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, г. Санкт-Петербург
Russian Federation
Russian Federation
D. I. Danilchenko
Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, г. Санкт-Петербург
Russian Federation
Russian Federation
References
1. Давыдов МИ, Аксель ЕМ. Статистика злокачественных новообразований в России и странах СНГ в 2004 году. Вестн РОНЦ им Блохина РАМН 2006; 17(3): 52-89
2. Аполихин ОИ, Какорина ЕП, Сивков АВ и др. Состояние урологической заболеваемости в Российской Федерации по данным официальной статистики. Урология 2003; 3: 3-9
3. Лопаткин НА, Даренков СП, Чернышов ИВ и др. Диагностика и лечение рака мочевого пузыря. Урология 2004; 1: 12-17
4. Stetler – Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 1147-154
5. Kanayama H, Yokota K, Kurokawa Y. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 1359-1366
6. Forsyth PA, Wong H, Laing TD et al. Gelatinase–A (ММP-2), gelatinase-B (ММP-9) and membrane type matrix metalloproteinase-1 are involved in different aspects of the pathophysiology of different aspects of malignant gliomas. Brit J Cancer 1999; 79: 1828-1835
7. Sier CF, Casetta G, Verheijen JH et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 2000; 6: 2333-2340
8. Zucker S, Lysik R, Zarrabi H et al. Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 1995; 76: 700-708
Review
For citations:
Al-Shukri A.S., Danilchenko D.I. THE DIAGNOSTIC AND PROGNOSTIC VALUE OF THE DETERMINATION OF MATRIX-METALLOPROTEAS IN THE URINE OF PATIENTS WITH URINARY BLADDER CANCER. Nephrology (Saint-Petersburg). 2009;13(1):87-89. (In Russ.) https://doi.org/10.24884/1561-6274-2009-13-1-87-89
Views:
319
Email this article 